Broker recommendations for Eli Lilly & Co.
The Eli Lilly & Co. stock is rated at 1.375 (on a scale 1-3, where 1 is ‘strong buy‘ and 3 is ‘strong sell‘) from Wednesday 21 October, 2020 by a total of 16 brokers. This means that the consensus of the 16 different brokers is leaning toward to buy/moderate buy.
0 (0%) Underweight
0 (0%) Hold
6 (37.5%) Overweight
0 (0%) Buy
Price target by analysts
The 14 latest analyst estimates, per Wednesday 21 October, 2020, show the following high, low and average price targets.
Target Average: 172.36 USD
Target High: 200 USD
Target Low: 144 USD
Eli Lilly And Co (NYSE:LLY) Coverage Initiated by Analysts at Truist
Saturday, 24 October 2020, 14:55:11
Truist assumed coverage on shares of Eli Lilly And Co (NYSE:LLY) in a research report sent to investors on Friday morning, The Fly reports. The firm issued a buy rating and a $180.00 price target on the stock. A number of other equities research analysts have also issued reports on LLY. Morgan Stanley raised shares […]
— Transcript Daily
Saturday, 24 October 2020, 13:05:00
Summary List Placement The first approval of a COVID-19 drug in the US wasn’t quite a cause for celebration. US regulators approved the virus-fighting drug remdesivir on Thursday, greenlighting its use in hospitalized patients. The US Food and Drug Administration had given an emergency OK for the drug’s use in May. But it’s unclear how well remdesivir, marketed as Veklury, works for patients with COVID-19, the disease caused by the novel coronavirus. Studies respectively led by the US National Institutes of Health and the World Health Organization came to conflicting conclusions, with the WHO research casting doubt on the drug’s benefits. “It has an effect, but it doesn’t really have an amazing effect that people were hoping it would have,” Dr. Walid Gellad, director for the Center for Pharmaceutical Policy and Prescribing at the University of Pittsburgh, told Business Insider in a Friday phone interview. In squaring the findings of the main studies on remdesivir, longtime drug discovery researcher Derek Lowe wrote that “for remdesivir, it looks like the argument now is ‘Does it help a bit or just not at all?'” Despite that uncertainty, one thing is clear: Remdesivir’s manufacturer, the California biotech giant Gilead Sciences, is in a prime position to sell billions of dollars worth of the drug.
— Business Insider
Friday, 23 October 2020, 17:46:33
This report provides in-depth study on the current state of the Global Livestock Animal Vaccine Market 2020-2025. Key players in the Global Livestock Animal Vaccine Market have been identified through the secondary research and their market share has been determined
Active Pharmaceutical Ingredients (API) Market Size 2020 Industry Price Trend, Industry Outlook, Business Growth, Report Latest Research| Pfizer Inc., Novartis AG, Sanofi, Teva Pharmaceutical Industries Ltd., Eli Lilly and Company
Friday, 23 October 2020, 09:21:18
The Active Pharmaceutical Ingredients (API) Market Research Report delivers all-inclusive analysis of the market structure along with forecast of the diverse segments and sub-segments of the market. Active Pharmaceutical Ingredients (API) Market 2020 Industry Research Report is an in-depth and
FDA Approves Gilead’s Remdesivir To Treat COVID-19 Despite Data Showing Drug Doesn’t Work
Friday, 23 October 2020, 00:00:00
FDA Approves Gilead’s Remdesivir To Treat COVID-19 Despite Data Showing Drug Doesn’t Work Tyler Durden Thu, 10/22/2020 – 18:00 Despite reams of data from an international WHO study raising serious questions about its efficacy, the FDA has finally approved the use of Gilead Science’s remdesivir – a powerful antiviral originally developed to treat ebola – for the treatment of COVID-19, making it the first such drug approved to treat the virus in the US. The FDA first granted the drug emergency authorization in May, allowing hospitals and doctors to use the drug even though by all accounts it wasn’t that widely used. President Trump received one course of remdesivir along with several other COVID-19 therapies after contracting the virus. Doctors also gave the president dexamethasone, a steroid that has a much better track record for treating the virus, according to the available data. Trump also received an experimental drug from Regeneron, which, along with Eli Lilly, has filed for emergency use approval for its COVID-19 antibody treatment.
— Zero Hedge
We recommend that you check out Capital.com as they have a very good selection of stocks available for both going short and long.